Oppenheimer fund sheds biotech holdings

The travails of the D. Blech companies aside, share price pressures in the sector in recent weeks more likely have resulted from the unwinding of

Read the full 256 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE